The document discusses Avenova (formerly i-Lid Cleanser), a new over-the-counter eyelid and lash cleanser containing 0.01% pure hypochlorous acid developed by NovaBay Pharmaceuticals to treat blepharitis, meibomian gland dysfunction, and associated dry eye conditions. Avenova is designed to kill pathogens commonly found on the eyelids and lashes through its antimicrobial properties while also neutralizing toxins and suppressing inflammation. Clinical trials have demonstrated Avenova's fast killing of bacteria, yeast, and ability to disrupt biofilms compared to other lid cleansers, with a higher therapeutic index and lower toxicity than
Intracanal medicaments are used to disinfect the root canal system, reduce microorganisms, and render canal contents inert. Common intracanal medicaments include phenolics, eugenol, parachlorophenol, formocresol, glutaraldehyde, calcium hydroxide, and antibiotics. The ideal intracanal medicament is an effective germicide and fungicide that remains stable, has prolonged antimicrobial effects, and does not interfere with tissue repair or stain tooth structure. However, no single agent fulfills all these criteria.
CCNPWT (Closed Cyclic Negative Pressure Wound Therapy) is a wound management technique that uses negative pressure to promote wound healing. It involves placing a foam dressing in the wound, sealing it with a drape, and applying controlled negative pressure through a tube. This removes excess fluid, stimulates blood flow, and encourages granulation tissue growth while keeping the wound moist and protected. CCNPWT can help heal wounds like pressure ulcers, burns, diabetic ulcers, surgical wounds, and more by creating an environment that supports healing on a cellular level.
This document summarizes information about Avenova, a lid and lash cleanser produced by NovaBay Pharmaceuticals. It discusses blepharitis and meibomian gland dysfunction that Avenova treats. Avenova uses Neutrox technology, which contains pure hypochlorous acid that kills bacteria quickly without generating resistance. It is more effective than other lid cleansers and has anti-toxin and anti-biofilm properties. The document provides details on NovaBay as a company and clinical cases that demonstrate the effectiveness of Avenova in treating blepharitis and improving symptoms.
This document summarizes information about Avenova, a lid and lash cleanser produced by NovaBay Pharmaceuticals. It discusses blepharitis and meibomian gland dysfunction that Avenova treats. Avenova uses Neutrox technology, which contains pure hypochlorous acid that kills bacteria quickly without generating resistance. It is more effective than other lid cleansers and has anti-toxin and anti-biofilm properties. The document provides examples of patients whose blepharitis and dry eye symptoms improved after using Avenova.
Vitiligo research foundation-achievements,_present,_future_trends_2017VR Foundation
The document discusses achievements and future trends in vitiligo research by the Vitiligo Research Foundation. It summarizes the Foundation's approach of understanding repigmentation through collecting clinical data and biosamples, open-source data sharing, and disseminating knowledge. It outlines current vitiligo treatments including phototherapy and experimental options. It also discusses the Foundation's work developing an electronic health record, vitiligo biobank, and data analysis to help accelerate drug development for vitiligo. Emerging trends highlighted include increased patient self-treatment options using home phototherapy and nutraceuticals.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
Intracanal medicaments are used to disinfect the root canal system, reduce microorganisms, and render canal contents inert. Common intracanal medicaments include phenolics, eugenol, parachlorophenol, formocresol, glutaraldehyde, calcium hydroxide, and antibiotics. The ideal intracanal medicament is an effective germicide and fungicide that remains stable, has prolonged antimicrobial effects, and does not interfere with tissue repair or stain tooth structure. However, no single agent fulfills all these criteria.
CCNPWT (Closed Cyclic Negative Pressure Wound Therapy) is a wound management technique that uses negative pressure to promote wound healing. It involves placing a foam dressing in the wound, sealing it with a drape, and applying controlled negative pressure through a tube. This removes excess fluid, stimulates blood flow, and encourages granulation tissue growth while keeping the wound moist and protected. CCNPWT can help heal wounds like pressure ulcers, burns, diabetic ulcers, surgical wounds, and more by creating an environment that supports healing on a cellular level.
This document summarizes information about Avenova, a lid and lash cleanser produced by NovaBay Pharmaceuticals. It discusses blepharitis and meibomian gland dysfunction that Avenova treats. Avenova uses Neutrox technology, which contains pure hypochlorous acid that kills bacteria quickly without generating resistance. It is more effective than other lid cleansers and has anti-toxin and anti-biofilm properties. The document provides details on NovaBay as a company and clinical cases that demonstrate the effectiveness of Avenova in treating blepharitis and improving symptoms.
This document summarizes information about Avenova, a lid and lash cleanser produced by NovaBay Pharmaceuticals. It discusses blepharitis and meibomian gland dysfunction that Avenova treats. Avenova uses Neutrox technology, which contains pure hypochlorous acid that kills bacteria quickly without generating resistance. It is more effective than other lid cleansers and has anti-toxin and anti-biofilm properties. The document provides examples of patients whose blepharitis and dry eye symptoms improved after using Avenova.
Vitiligo research foundation-achievements,_present,_future_trends_2017VR Foundation
The document discusses achievements and future trends in vitiligo research by the Vitiligo Research Foundation. It summarizes the Foundation's approach of understanding repigmentation through collecting clinical data and biosamples, open-source data sharing, and disseminating knowledge. It outlines current vitiligo treatments including phototherapy and experimental options. It also discusses the Foundation's work developing an electronic health record, vitiligo biobank, and data analysis to help accelerate drug development for vitiligo. Emerging trends highlighted include increased patient self-treatment options using home phototherapy and nutraceuticals.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
Intervento del Dottor Luca Avoni a Sicsso 2018Luca Avoni
Corneal scraping is an important diagnostic tool for infectious keratitis that allows identification of the infectious agent, such as bacteria, fungi, or Acanthamoeba. Identification of the agent guides selection of targeted antibiotic or antifungal treatment and improves recovery chances. Corneal scraping should be performed before starting antibiotic therapy, on central or deep ulcers, or in young or immunosuppressed patients. It has a high rate of positive results and identification of agents including Staphylococcus, Pseudomonas, Candida, and Fusarium. Targeted topical or systemic therapy is selected based on agent identified, with close follow-up of patients required.
A hypochlorous acid lid cleanser provides a novel way to clean the eyelids and reduce bacteria. Two doctors have found it to be effective for managing blepharitis with excellent results and high patient acceptance. It reduces the need for antibiotic and steroid drops. Laboratory studies show the cleanser has broad-spectrum activity against ocular bacteria and does not irritate tissues. The doctors recommend its twice daily use to resolve blepharitis symptoms within two weeks without recurrence in many patients.
Katy Najafi and Steve Lichtenstein Ophthalmology TimeJeff Gilbert
A new hypochlorous acid lid cleanser provides a safe and effective alternative for cleansing the eyelids and surrounding skin. Two doctors found the cleanser to be very helpful in managing blepharitis. It reduced the need for antibiotic and steroid drops, and patients reported good results and found it refreshing to use. The cleanser uses hypochlorous acid, a natural antimicrobial produced by white blood cells. Laboratory tests showed it effectively kills pathogens including MRSA without toxicity to tissues. Both doctors recommend the cleanser for regular daily use to control blepharitis.
Dr. Rahul VC Tiwari - Fellowship In Orthognathic Surgery - Jubilee Mission Medical College Hospital and Research Center, Thrissur, Kerala - 28th publication IJMOR 1st name
NanoSynergy® developed technology to accelerate fluids faster than the speed of sound to 1500 ft/sec for 3-5 nanoseconds to create extreme shear and impact forces necessary for molecular dispersion without excessive heat or breaking chemical bonds.
“The combination of applied nanotechnology with any
compound, molecule, mixture or fluid to deliver an end product of smaller particle size to yield greater bioavailability and efficacy.”
Features for Manufacturers
Enhances existing products & formulations by creating stable NanoSyzed™ solutions, emulsions, dispersions
Reduce amount of raw materials and increase the absorption of nutrients into the body by stable biophysical “digestion” of agglomerates
Competitive marketing edge with efficient integration with existing processing to create superior, stable, and patentable products
Benefits for Consumer
No water or large tablets (40% of Americans experience difficulty)
Exceptional product performance – faster acting (e.g. B12 Spray vs Shot)
Prevent wasting of money on useless aggregated products
Our particle size analysis of 100’s of leading nutraceutical products shows that nearly the entire industry could benefit from the patented technology developed by NanoSynergy Worldwide, Inc.
The lead technology platform, NanoSynergy®, is already proven as a commercially viable system that works effectively for a variety of water soluble and insoluble nutraceutical compounds.
Our patented technology can be incorporated into common dosage forms for substantial improvements in product performance.
NanoSynergy® has the potential to dramatically improve the marketability of a vast range of products that have issues with solubility, stability, bioavailability, and efficacy.
Nanoemulsion : A versatile drug delivery systemDeeptiMSati
Paul Ehrlich in 1902 proposed targeted drug delivery similar to a "magic bullet". An ideal drug delivery system maximizes therapeutic effects while minimizing toxicity. Novel drug delivery systems (NDDS) have evolved from simple mixtures and pills to more sophisticated systems. Nanoemulsions are dispersions of at least two immiscible fluids as droplets smaller than 1 micrometer. They are stable alternatives to liposomes for drug delivery through various routes of administration such as oral, topical, nasal and ocular delivery. While nanoemulsions increase bioavailability and target delivery, their manufacturing is expensive and stability can be an issue.
This document summarizes a presentation on chronic wound management in primary care. It discusses identifying the etiology of chronic wounds, assessing systemic factors, executing basic treatment including wound bed preparation and dressing selection, providing patient education, and establishing long term management plans. Specific guidance is provided on managing common chronic wound types like diabetic foot ulcers, venous leg ulcers, and pressure injuries. Data on chronic wound cases in one primary care setting is also presented, showing most wounds are chronic and related to diabetes. The full presentation is accessible online for free.
Upstream Viral Safety – Protect your bioreactor with Virus FiltrationMilliporeSigma
This poster summarizes the performance of a filter specifically developed for virus removal from chemically defined cell culture media. The filter removes high levels of virus, mycoplasma and bacteria without impacting cell growth, antibody titer, or protein quality. The filter has robust performance over a broad range of conditions offering an effective, easy to implement solution for media treatment.
The document discusses sterilization and disinfection. It defines sterilization as removing all living microorganisms and disinfection as destroying or removing pathogenic organisms. The objective of sterilization is to prevent contamination, infection, and decay by removing microorganisms from materials or areas. Important historical figures who contributed to understanding microbes and disease include Louis Pasteur, Robert Koch, Joseph Lister. Proper sterilization is important in dentistry to prevent transmission of diseases like herpes, syphilis, and candidiasis. An ideal disinfectant must be fast-acting, non-toxic, and inexpensive. Methods of microbial control include physical agents like heat and radiation, as well as chemical agents.
NanoSynergy Worldwide develops and markets science-based formulations using proprietary nano-processing technology to create effective health and wellness products. Their patented NanoSynergy process breaks down particle aggregates into sub-1 nanometer sizes without excessive heat, improving absorption and efficacy. Analysis shows their spray vitamin products are thousands of times smaller than competitors, demonstrating superior performance in studies. Their business strategy is to partner with companies to license the technology and help develop competitive products through their efficient product development pipeline.
Anti-Adhesion and Anti-Biofilm Effectiveness of Disinfectants Used In Hemodia...IJERA Editor
Biofilms are communities of microorganisms attached to a surface and included in an extracellular matrix making it resistant to exogenous deleterious agents. The aim of this study is to evaluate the anti-adhesive and anti-biofilm effect of five commercials disinfectants having different active principles (hydrogen peroxide, sodium hypochlorite, isopropyl alcohol and ethanol) on four Staphylococcus strains isolated from hemodialysis unit surfaces. The disinfectants anti-adhesive effect was estimated to an exceeding rate 70% for the various studied dilutions and 90% towards the pure products. Whereas the anti-biofilm effect showed an elimination rate varying between 10 % and 95 % according to the following parameters: active principle, time of contact, concentration and bacterial strain. Our study demonstrated that all tested products have an interesting anti-adhesive effect and that the peroxide of hydrogen is endowed with important anti-biofilm efficiency, followed by the alcoholic products and the sodium hypochlorite.
Developing a single use adenovirus-vectored vaccine process through public-pr...Merck Life Sciences
This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations.
We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing.
In this webinar, you will learn:
- The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing.
- The solutions that overcame those challenges.
- How public-private collaborations can accelerate vaccine process development.
Developing a single use adenovirus-vectored vaccine process through public-pr...MilliporeSigma
This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations.
We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing.
In this webinar, you will learn:
- The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing.
- The solutions that overcame those challenges.
- How public-private collaborations can accelerate vaccine process development.
Steve Berger - Manufacturing & Development UpdateJohn Blue
Manufacturing & Development Update - Steve Berger, Development Director, Aptimmune, from the 2018 Aptimmune Pre-AASV Symposium, March 2, 2018, San Diego, CA, USA.
More presentations at http://www.swinecast.com/2018-aptimmune-symposium-aasv
The document discusses research on predicting the quality of post-harvest fruit using non-destructive methods. Researchers studied the degradation kinetics of external quality attributes (appearance, color) and internal attributes (firmness, sugars, acids) in three varieties of apples stored at 5°C. They found correlations between the degradation of external and internal attributes, with some internal attributes following zero-order kinetics and others following first-order kinetics similar to external attributes. This suggests external quality monitoring could allow prediction of internal quality changes over storage time.
Nano pesticide: An Emerging Tool for Pest MagagementGopal Golvankar
This document discusses nanopesticides as an emerging tool for pest management. It begins with an introduction to nanotechnology and its applications. It then discusses how nanotechnology can be used in insecticide formulations through various methods like nanoemulsions, nano suspensions, nanoencapsulation, and nanoparticles. Several case studies are presented that demonstrate the effectiveness of different nanopesticide formulations against various insect pests. The conclusion is that nanopesticides can provide green alternatives for pest control and help reduce pesticide waste, pollution, and increase product stability and efficiency. Future areas of focus include further exploiting green chemistry with nano-reformulated pesticides, developing commercial scale-up processes, field comparisons to existing products, and environmental
This document summarizes a case study of neonatal osteomyelitis that developed as an unusual complication following extraction of a natal tooth. A 52-day old infant presented with a painful swelling and abscess in the lower jaw that had been present for a month. The infant had a natal tooth extracted at 11 days of age. CT scan and bloodwork confirmed osteomyelitis caused by Staphylococcus aureus. The infant was treated with intravenous vancomycin for 3 weeks followed by 1 week of oral vancomycin, resulting in healing of the extraoral and intraoral sites. This case highlights the rare but important potential for osteomyelitis to develop after natal tooth extraction.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
- Avenova is a new prescription eye drop product containing hypochlorous acid that is being used to treat common eye conditions like blepharitis and dry eye syndrome, especially in elderly patients.
- It is described as a potent and effective new solution by Dr. Arthur Epstein for alleviating inflammation of the eyelids associated with blepharitis and dry eye symptoms.
- Hypochlorous acid is naturally produced by the body to fight microbes and Avenova contains a stabilized form of it that is well-tolerated on the ocular surface.
Intervento del Dottor Luca Avoni a Sicsso 2018Luca Avoni
Corneal scraping is an important diagnostic tool for infectious keratitis that allows identification of the infectious agent, such as bacteria, fungi, or Acanthamoeba. Identification of the agent guides selection of targeted antibiotic or antifungal treatment and improves recovery chances. Corneal scraping should be performed before starting antibiotic therapy, on central or deep ulcers, or in young or immunosuppressed patients. It has a high rate of positive results and identification of agents including Staphylococcus, Pseudomonas, Candida, and Fusarium. Targeted topical or systemic therapy is selected based on agent identified, with close follow-up of patients required.
A hypochlorous acid lid cleanser provides a novel way to clean the eyelids and reduce bacteria. Two doctors have found it to be effective for managing blepharitis with excellent results and high patient acceptance. It reduces the need for antibiotic and steroid drops. Laboratory studies show the cleanser has broad-spectrum activity against ocular bacteria and does not irritate tissues. The doctors recommend its twice daily use to resolve blepharitis symptoms within two weeks without recurrence in many patients.
Katy Najafi and Steve Lichtenstein Ophthalmology TimeJeff Gilbert
A new hypochlorous acid lid cleanser provides a safe and effective alternative for cleansing the eyelids and surrounding skin. Two doctors found the cleanser to be very helpful in managing blepharitis. It reduced the need for antibiotic and steroid drops, and patients reported good results and found it refreshing to use. The cleanser uses hypochlorous acid, a natural antimicrobial produced by white blood cells. Laboratory tests showed it effectively kills pathogens including MRSA without toxicity to tissues. Both doctors recommend the cleanser for regular daily use to control blepharitis.
Dr. Rahul VC Tiwari - Fellowship In Orthognathic Surgery - Jubilee Mission Medical College Hospital and Research Center, Thrissur, Kerala - 28th publication IJMOR 1st name
NanoSynergy® developed technology to accelerate fluids faster than the speed of sound to 1500 ft/sec for 3-5 nanoseconds to create extreme shear and impact forces necessary for molecular dispersion without excessive heat or breaking chemical bonds.
“The combination of applied nanotechnology with any
compound, molecule, mixture or fluid to deliver an end product of smaller particle size to yield greater bioavailability and efficacy.”
Features for Manufacturers
Enhances existing products & formulations by creating stable NanoSyzed™ solutions, emulsions, dispersions
Reduce amount of raw materials and increase the absorption of nutrients into the body by stable biophysical “digestion” of agglomerates
Competitive marketing edge with efficient integration with existing processing to create superior, stable, and patentable products
Benefits for Consumer
No water or large tablets (40% of Americans experience difficulty)
Exceptional product performance – faster acting (e.g. B12 Spray vs Shot)
Prevent wasting of money on useless aggregated products
Our particle size analysis of 100’s of leading nutraceutical products shows that nearly the entire industry could benefit from the patented technology developed by NanoSynergy Worldwide, Inc.
The lead technology platform, NanoSynergy®, is already proven as a commercially viable system that works effectively for a variety of water soluble and insoluble nutraceutical compounds.
Our patented technology can be incorporated into common dosage forms for substantial improvements in product performance.
NanoSynergy® has the potential to dramatically improve the marketability of a vast range of products that have issues with solubility, stability, bioavailability, and efficacy.
Nanoemulsion : A versatile drug delivery systemDeeptiMSati
Paul Ehrlich in 1902 proposed targeted drug delivery similar to a "magic bullet". An ideal drug delivery system maximizes therapeutic effects while minimizing toxicity. Novel drug delivery systems (NDDS) have evolved from simple mixtures and pills to more sophisticated systems. Nanoemulsions are dispersions of at least two immiscible fluids as droplets smaller than 1 micrometer. They are stable alternatives to liposomes for drug delivery through various routes of administration such as oral, topical, nasal and ocular delivery. While nanoemulsions increase bioavailability and target delivery, their manufacturing is expensive and stability can be an issue.
This document summarizes a presentation on chronic wound management in primary care. It discusses identifying the etiology of chronic wounds, assessing systemic factors, executing basic treatment including wound bed preparation and dressing selection, providing patient education, and establishing long term management plans. Specific guidance is provided on managing common chronic wound types like diabetic foot ulcers, venous leg ulcers, and pressure injuries. Data on chronic wound cases in one primary care setting is also presented, showing most wounds are chronic and related to diabetes. The full presentation is accessible online for free.
Upstream Viral Safety – Protect your bioreactor with Virus FiltrationMilliporeSigma
This poster summarizes the performance of a filter specifically developed for virus removal from chemically defined cell culture media. The filter removes high levels of virus, mycoplasma and bacteria without impacting cell growth, antibody titer, or protein quality. The filter has robust performance over a broad range of conditions offering an effective, easy to implement solution for media treatment.
The document discusses sterilization and disinfection. It defines sterilization as removing all living microorganisms and disinfection as destroying or removing pathogenic organisms. The objective of sterilization is to prevent contamination, infection, and decay by removing microorganisms from materials or areas. Important historical figures who contributed to understanding microbes and disease include Louis Pasteur, Robert Koch, Joseph Lister. Proper sterilization is important in dentistry to prevent transmission of diseases like herpes, syphilis, and candidiasis. An ideal disinfectant must be fast-acting, non-toxic, and inexpensive. Methods of microbial control include physical agents like heat and radiation, as well as chemical agents.
NanoSynergy Worldwide develops and markets science-based formulations using proprietary nano-processing technology to create effective health and wellness products. Their patented NanoSynergy process breaks down particle aggregates into sub-1 nanometer sizes without excessive heat, improving absorption and efficacy. Analysis shows their spray vitamin products are thousands of times smaller than competitors, demonstrating superior performance in studies. Their business strategy is to partner with companies to license the technology and help develop competitive products through their efficient product development pipeline.
Anti-Adhesion and Anti-Biofilm Effectiveness of Disinfectants Used In Hemodia...IJERA Editor
Biofilms are communities of microorganisms attached to a surface and included in an extracellular matrix making it resistant to exogenous deleterious agents. The aim of this study is to evaluate the anti-adhesive and anti-biofilm effect of five commercials disinfectants having different active principles (hydrogen peroxide, sodium hypochlorite, isopropyl alcohol and ethanol) on four Staphylococcus strains isolated from hemodialysis unit surfaces. The disinfectants anti-adhesive effect was estimated to an exceeding rate 70% for the various studied dilutions and 90% towards the pure products. Whereas the anti-biofilm effect showed an elimination rate varying between 10 % and 95 % according to the following parameters: active principle, time of contact, concentration and bacterial strain. Our study demonstrated that all tested products have an interesting anti-adhesive effect and that the peroxide of hydrogen is endowed with important anti-biofilm efficiency, followed by the alcoholic products and the sodium hypochlorite.
Developing a single use adenovirus-vectored vaccine process through public-pr...Merck Life Sciences
This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations.
We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing.
In this webinar, you will learn:
- The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing.
- The solutions that overcame those challenges.
- How public-private collaborations can accelerate vaccine process development.
Developing a single use adenovirus-vectored vaccine process through public-pr...MilliporeSigma
This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations.
We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing.
In this webinar, you will learn:
- The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing.
- The solutions that overcame those challenges.
- How public-private collaborations can accelerate vaccine process development.
Steve Berger - Manufacturing & Development UpdateJohn Blue
Manufacturing & Development Update - Steve Berger, Development Director, Aptimmune, from the 2018 Aptimmune Pre-AASV Symposium, March 2, 2018, San Diego, CA, USA.
More presentations at http://www.swinecast.com/2018-aptimmune-symposium-aasv
The document discusses research on predicting the quality of post-harvest fruit using non-destructive methods. Researchers studied the degradation kinetics of external quality attributes (appearance, color) and internal attributes (firmness, sugars, acids) in three varieties of apples stored at 5°C. They found correlations between the degradation of external and internal attributes, with some internal attributes following zero-order kinetics and others following first-order kinetics similar to external attributes. This suggests external quality monitoring could allow prediction of internal quality changes over storage time.
Nano pesticide: An Emerging Tool for Pest MagagementGopal Golvankar
This document discusses nanopesticides as an emerging tool for pest management. It begins with an introduction to nanotechnology and its applications. It then discusses how nanotechnology can be used in insecticide formulations through various methods like nanoemulsions, nano suspensions, nanoencapsulation, and nanoparticles. Several case studies are presented that demonstrate the effectiveness of different nanopesticide formulations against various insect pests. The conclusion is that nanopesticides can provide green alternatives for pest control and help reduce pesticide waste, pollution, and increase product stability and efficiency. Future areas of focus include further exploiting green chemistry with nano-reformulated pesticides, developing commercial scale-up processes, field comparisons to existing products, and environmental
This document summarizes a case study of neonatal osteomyelitis that developed as an unusual complication following extraction of a natal tooth. A 52-day old infant presented with a painful swelling and abscess in the lower jaw that had been present for a month. The infant had a natal tooth extracted at 11 days of age. CT scan and bloodwork confirmed osteomyelitis caused by Staphylococcus aureus. The infant was treated with intravenous vancomycin for 3 weeks followed by 1 week of oral vancomycin, resulting in healing of the extraoral and intraoral sites. This case highlights the rare but important potential for osteomyelitis to develop after natal tooth extraction.
1. AVENOVA
(formerly i-Lid™
Cleanser)
A NEW DIMENSION IN LID AND LASH HYGIENE
NovaBay Pharmaceuticals, Inc.
(New York Stock Exchange: NBY)
For more information contact:
Ron Najafi, Ph.D.
CEO & Founder
And consult: www.Avenova.com
2. The San Francisco Bay Area
Home to NovaBay Pharmaceuticals
(A view from our facilities)
3. NovaBay Pharmaceuticals
Employees: 28, founded in 2000 by Ron Najafi, Ph.D. (chemist)
NovaBay Dedicated Sales Force: 37, all across the US
Location: Emeryville, CA
Capital Structure: Public Company, listed on NYSE: NBY
Focus: Non-Antibiotic Antimicrobials
Marketed products (Neutrox platform)
– AVENOVA: (formerly i-Lid™ Cleanser ) . Lid & Lash Hygiene, Blepharitis,
MGD and Dry Eye.
– NeutroPhase: Diabetic Ulcer, Venous and Pressure Ulcers, including NF
– CelleRx: Burn associated with Post Laser Resurfacing
Pre-Market Products (Aganocide platform)
– Bladder Irrigation Solution for patients with Spinal Cord Injury and recurrent
blockage and encrustation
– Skin Infection (Impetigo and Acne)
Global Partnerships: PBE (in the US), IHT (USA), Galderma (France), Virbac
(France), Pioneer Pharma (China and Southeast Asia), Shin Poong (Korea), Biopharm
(North African and Middle East), Alpha Pharma (Ukraine) and Sarmedic (Israel)
12. Blepharitis / Meibomian Gland Dysfunction/
Associated Dry Eye / Pre-Operative Lid
Hygiene
Chronic lid & lash hygiene
- 24 million blepharitis patients
- 6.5 million MGD dry eye patients
- 3 million cataract patients
- 1.5 million refractive surgery patients
Total Potential Market: $700 million
13. Antibiotics (topical or systemic)
Steroid (topical or systemic)
Warm Eye Compress to help with
Meibomian Glands
Gland Expression
Food supplements such as Omega 3 fatty
Acid
No FDA approved Therapy
Standard of Care includes
21. Avenova (formerly i-Lid™
Cleanser)
for Conditions of the Lids and Lashes
Proprietary Technology
– Neutrox : NovaBay Proprietary (>99% Pure) 0.01% Pure (99%)
hypochlorous solution in saline is by prescription only.
– No hypochlorite impurity, which is often present in OTC
solutions.
– No resistance is expected based on novel mechanism of
action
Significant Market / Poorly Served
– Eyelid hygiene therapy, part of the treatment for blepharitis
– Currently marketed products have little to no benefit
– 4% of 18 – 22 year olds
– 71% of 65+ year olds
– U.S. Market Estimate of $500+ mil
24. Organism (ATCC number) Time to Kill %Reduction
Aspergilus brasiliensis 16404 60 seconds >99.99%
Bacteroides fragilis 25285 60 seconds >99.999%
Candida albicans 10231 60 seconds >99.99%
Clostridium perfingens 13124 60 seconds >99.99%
Enterobacter aerogenes 51697 60 seconds >99.999%
Enterococcus faecium (VRE) 51559 60 seconds >99.99%
Haemophilus influenzae 49144 60 seconds >99.999%
Klebsiella pneumoniae 10031 60 seconds >99.999%
Proteus mirabilis 14153 60 seconds >99.999%
Pseudomonas aeruginosa 27853 60 seconds >99.9999%
Serratia marcescens 14756 60 seconds >99.999%
Corynebacterium amycolatum 49368 60 seconds >99.99%
Staphylococcus aureus (MRSA) 33591 60 seconds >99.999%
Staphylococcus aureus 29213 60 seconds >99.999%
Staphylococcus epidermidis 12228 60 seconds >99.999%
Staphylococcus haemolyticus 29970 60 seconds >99.99%
Staphylococcus hominis 27844 60 seconds >99.99%
Staphylococcus saprophyticus 35552 60 seconds >99.99%
Streptococcus pyogenes 49399 60 seconds >99.99%
Propionibacterium acnes 29399 60 seconds >99.999%
Vibrio vulnificus 27562 60 seconds >99.999%
Neutrox®
NovaBay’s Proprietary Pure (>99%), 0.01% hypochlorous Acid in saline.
Skin pathogens are highlighted. The CLSI guideline for evaluating the bactericidal activity of an antimicrobial agent was adapted for this study. A 500 ul aliquot of each test organism was
added to separate tubes containing 5 mL AVENOVA (final inoculum 107 CFU/mL). After 1 min, a 30 ul aliquot was removed from each tube and diluted 1:10 in Dey/Engley (D/E) neutralizing
broth, followed by three additional ten-fold dilutions in D/E. This procedure was repeated at 4 minutes and 10 minutes post-inoculation. Each dilution was plated onto the appropriate agar
media in duplicate for quantitation. Plates were then incubated under the appropriate conditions for each organism, and CFU were counted. Details of the procedures can be found in Report
#: FD-1403R.00
Excellent in-
solution
activity
against a
broad range
of pathogens
Fast acting
onset of
activity
Effective
against
pathogens
commonly
found on the
lids & lashes
25. 27
Avenova™ demonstrated excellent activity in solution
compared with the market leading lid and lash cleanser*
Organism S. aureus MRSA S. epidermidis S. haemolyticus P. acnes
NovaBay
Avenova®
< 1 minute < 1 minute < 1 minute < 1 minute < 1 minute
OcuSoft® Lid
Scrub Foam
> 30 minute > 30 minute > 30 minute > 30 minute > 30 minute
NovaBay’s in-house methodology for determining therapeutic index was utilized.
fibroblast cells were used to assess safety. Each agent was serially diluted to arrive at a “cell safe” concentration. At that concentration,
antimicrobial time kill was measured vs. various microorganism (shown above). More on this methodology at:
The In Vitro Antimicrobial Activity of Wound and Skin Cleansers at Nontoxic Concentrations
Suriani Abdul Rani, MS; Russell Hoon; Ramin (Ron) Najafi, PhD; Behzad Khosrovi, PhD; Lu Wang, PhD; and Dmitri Debabov, PhD
ADVANCES IN SKIN & WOUND CARE, FEBRUARY 2014, VOL. 27 NO. 2, page 66-69
26. Avenova has higher Therapeutic
Index than Betadine
• Fast acting
onset of
microbial
activity
• Extremely
low toxicity
levels
• 1,000 times
less toxicity
than
Betadine®
28
Tested AVENOVA® Betadine® Surgical
Scrub (Povidone-
iodine, 7.5%)
Nontoxic
Dilution
1:10 1:10,000
Time to 4 log10
kill
<1 minute >24 hours
Tested Against S. aureus ATCC 33591
*Antimicrobial Activity Comparison of Pure Hypo-chlorous Acid (0.01) with other Wound and Skin Cleansers at Non-Toxic Concentrations,
Russell Hoon, Suriani Abdul Rani, Ramin Najafi, Lu Wang, Dmitri Debabov; SAWC Spring 2013 and WHD 2013
The In Vitro Antimicrobial Activity of Wound and Skin Cleansers at Nontoxic Concentrations
Suriani Abdul Rani, MS; Russell Hoon; Ramin (Ron) Najafi, PhD; Behzad Khosrovi, PhD; Lu Wang, PhD; and Dmitri Debabov, PhD
ADVANCES IN SKIN & WOUND CARE, FEBRUARY 2014, VOL. 27 NO. 2, page 66-69
27. Bacteria / Biofilm Complicates Blepharitis
29
• Hypothesis is that
bacterial biofilm
plays a significant
role in delaying
wound healing
(Mertz – Wounds – May
2003)
A scanning electron micrograph of a porcine wound surface
with Staphylococcus aureus biofilm (6000X)
29. 31
NovaBay Avenova® has Potent Anti-biofilm
Activity Compared to Saline
• In vitro Biofilm of P. fluorescens breaks up upon
introduction of Avenova®
SALINE (control) NovaBay AVENOVA®
For literature references pointing to anti-biofilm activity of Avenova
Click here
30. Hypochlorous Acid
Hypochlorous acid
(HOCL) released from
neutrophil cells
Part of body’s immune
response
Kills microorganisms
Neutralizes toxins
released from pathogens
and inflammatory
mediators
– helps suppress the body’s
inflammatory response
32
neutrophil
cell
HOCL
33. Representation of human cell response to
bacteria-produced toxins
35
Biological reactivity of hypochlorous acid: Implications for microbicidal mechanisms of leukocyte myeloperoxidase
J. MICHAEL ALBRICH, CAROL A. MCCARTHY, AND JAMES K. HURST*
Proc. National Acad. Sci. Vol. 78, No. 1, pp. 210-214, January 1981
34. Representation of the Mechanism of Action of
Hypochlorous .01% in In-Vitro Models
Kills
bacteria
Blocks
bacteria
produced
toxins
Blocks
human
cell
produced
pro-
inflammat
ory
mediators
Different effects of hypochlorous acid on human neutrophil metalloproteinases: activation of collagenase and inactivation of collagenase and
gelatinase. Michaelis J1, Vissers MC, Winterbourn CC., Arthritis Rheum. 1994 Mar;37(3):424-7
Inhibition of collagenase activity by N-chlorotaurine, a product of activated neutrophils. Davies JM1, Horwitz DA, Davies KJ. Department of Medicine,
Albany Medical College, New York 12208.
35. Dx of DES and Blepharitis:c/o irritation, pain; used Maxitrol drops and
ointment for 2 wks + warm compress and eye scrub with Baby Shampoo. Was
shown how to clean his lids and lashes in the office with Saline.
Still returned 2 wks later with similar symptoms. Maxitrol was d/c’d and
Avenova given. After 2 wks RTC with improved symptoms and improved
clinically on Exam.
After Use of Baby Shampoo After use of Avenova
36. Typical Blepharitis Case
Vision:
– OD 20/30
– OS 20/20-
TAP: OD 21 OS 23
Exam:
– Blepharitis
– Debris on lashes
– Conjunctival
hyperemia
37. • From end of 2008 until end of 2012
• Patient was seen 25 times
• Between visits he would call and get Rx for Ab.
• Received courses of:
• Bacitracin, neomycin, polymyxin, tobradex,
maxitrol, zylet, oral doxy, used Ocusoft.
• Patient developed skin ulcer from Ocusoft use
• 10% of patients who use these over the counter
eye lid scrubs will develop contact dermatitis
• Eczema type reaction due to their detergent
based components
Patient Case History: Chronic Blepharitis
47. After 3 wks of use of Avenova™
fewer Demodex & better looking Lids and Lashes
48.
49.
50. Patients with acute or early stage meibomian gland
disease have a frothy tear film, or bubbles, which is
evident of soapy like substance here at the lid margin.
52. Staph aureus is a consistent Lipase producer
Breaking down natural lipids (triglycerides)
produced by Meibomian Glands
Bacteria Lipase activity is responsible for the
breakdown of lipid to fatty acids
– [Invest. Ophthalmol. Vis. Sci.April 1986 vol. 27 no. 4 486-491]
Assuming Lipase causes saponification of lipid
and conversion to fatty acid and soap. Can
Avenova breakdown Lipase and prevent
saponification (soap making)
53. In Laboratory Testing, Avenova™(formerly i-Lid
Cleanser) inactivates Rapidly Bacterial Lipase
Comparison of Bacterial Lipase Activity in the Presence of Eye Lid Cleansers
A. Epstein, L. Pang, K. Najafi-Tagol, R. Najafi, D. W. Stroman, D. Debabov.
Accepted for presentation at ARVO 2015
54. • Serial dilutions of AVENOVA™ were incubated for
1 h with S. aureus alpha-hemolysin toxin (1
ug/mL) and S. pyogenes streptokinase (175 u/mL)
• 0.1 ug/mL AVENOVA™ (1,000 dilution)
completely inactivated S. aureus alpha-hemolysin
toxin
• 0.001 ug/mL AVENOVA™ (100,000 dilution)
completely inactivated S. pyogenes streptokinase
Activity of AVENOVA™ against
Bacterial Toxins
55. Mechanism of Action
for Anti-Toxin and anti-Lipase Activity
S
S
R
R’
+ HOCl S
S
R
R’
O O
O O
S
S
R
R’
Cl
Cl
H2O
HOCl
Cl
Very Fast
Reaction
Kinetics of the reactions of hypochlorous acid and amino acid chloramines with thiols, methionine, and ascorbate. Free Radic. Biol. Med.
2001;30(5):572-9.
Herbert Spiegel, Advances in Clinical Chemistry, Vol 35, 2001, Academic Press
Oxidized
And unfolded Protein.
Highly water soluble and
non-immunogenic
Waldemar Gottardi, Dmitri Debabov and Markus Nagl, N-Chloramines, a Promising Class of Well-Tolerated Topical Anti-Infectives, Antimicrob.
Agents Chemother. 2013, 57(3):1107.
Staphylococcus aureus alpha toxin
56. Chronic use of antibiotic will
result in antibiotic resistant
strains… we must be vigilant !
59. To Open an account contact:
NovaBay by calling:
1-800-890-0329
Retail to patients: $30-40
If used according to instructions:
1st bottle will last 2 weeks
(2X per day application)
2nd bottle will last 1 month
(1X per day application)